Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy

Journal of the Canadian Urological Association

Volumn 3, Issue 6 SUPPL. 4, 2009, Pages

  Svatek, Robert S ^a   Siefker Radtke, Arlene ^a   Dinney, Colin P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849127221     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-7.
2. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-9.
3. Loehrer PJ, Sr., Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-73.
4. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19: 2638-46.
5. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-97.
6. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77.
7. Stenzl A, Cowan NC, De Santis M, et al. The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Eur Urol 2009; 55: 815-25.
8. Errazquin Saenz de Tejada L, Gonzalez Ferreira JA, Mesa Saenz CM, et al. [Palliative radiotherapy of bladder cancer]. Arch Esp Urol 1999; 52: 627-36.
9. Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 2000; 47: 379-88.
10. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatinum-based chemotherapy. J Urol 1994; 151: 598-600.; discussion 600-1.
11. Dodd PM, McCaffrey JA, Herr H et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999; 17: 2546-52.
12. Miller RS, Freiha FS, Reese JH, et al. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 1993; 150: 65-9.
13. Evans CP, Swanson DA. What to do if the lymph nodes are positive. Semin Urol Oncol 1996; 14: 96-102.
14. Herr HW, Donat SM. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 2001; 165: 62-4.; discussion 64.
15. Thompson IM. Re: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 2001; 166: 630.
16. Lebret T, Herve JM, Yonneau L, et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol 2002; 42: 344-9.; discussion 349.
17. Sweeney P, Millikan R, Donat M, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003; 169: 2113-7.
18. Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology 1982; 20: 390-2.
19. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004; 171: 145-8.
20. Abe T, Shinohara N, Harabayashi T, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007; 52: 1106-13.
21. Lehmann J, Suttmann H, Albers P, et al. Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05). Eur Urol 2009; 55: 1293-9.